Table 4.
Outcome events of fractures
| Outcome events | Reports (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SGLT2is | M | S | G | T | D | M + SGLT2is | S + SGLT2is | G + SGLT2is | T + SGLT2is | D + SGLT2is | |
| Congenital Anomaly | 1 (0.47) | 0 (0.00) | 1 (3.70) | 0 (0.00) | 0 (0.00) | 1 (0.48) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Death | 12 (5.61) | 87 (11.68) | 1 (3.70) | 4 (0.99) | 85 (9.84) | 73 (34.76) | 0 (0.00) | 0 (0.00) | 1 (3.70) | 0 (0.00) | 0 (0.00) |
| Disability | 22 (10.28) | 35 (4.70) | 2 (7.41) | 15 (3.69) | 63 (7.29) | 25 (11.90) | 11 (11.34) | 1 (6.25) | 2 (7.41) | 2 (20.00) | 2 (6.06) |
| Hospitalization | 118 (55.14) | 518 (69.53) | 21 (77.78) | 259 (63.79) | 604 (69.91) | 168 (80) | 53 (54.64) | 13 (81.25) | 17 (62.96) | 5 (50.00) | 24 (72.73) |
| Life‐Threatening | 11 (5.14) | 20 (2.68) | 1 (3.70) | 6 (1.48) | 9 (1.04) | 36 (17.14) | 8 (8.25) | 1 (6.25) | 1 (3.70) | 0 (0.00) | 3 (9.09) |
| Other Serious | 126 (58.88) | 284 (38.12) | 10 (37.04) | 232 (57.14) | 278 (32.18) | 157 (74.76) | 59 (60.82) | 5 (31.25) | 14 (51.85) | 5 (50.00) | 19 (57.58) |
| Required Intervention | 1 (0.47) | 8 (1.07) | 1 (3.70) | 1 (0.25) | 79 (9.14) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (10.00) | 0 (0.00) |
D, dipeptidyl peptidase‐4 inhibitors (sitagliptin, saxagliptin, and alogliptin); G, glucagon‐like peptide‐1 receptor agonists (exenatide, lixisenatide, liraglutide, albiglutide, and dulaglutide); M, metformin; S, sulfonylurea (glyburide, glipizide, and glimepiride); SGLT2is, sodium–glucose cotransporter 2 inhibitors; T, thiazolidinedione (pioglitazone and rosiglitazone).